All In Biotech

Drug Trial Radar · NCT06637514

A Phase 2 Study of JNT-517 in Adolescent Participants With Phenylketonuria

Last checked: Nov 19, 2026Latest source record: May 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

14

Actual

Start

Jul 16, 2025

Primary completion

May 8, 2026

Study completion May 8, 2026

Sponsor

Sponsor type
Industry
First posted
Oct 15, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 12 years, up to 17 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this Phase 2, randomized study is to assess the safety, tolerability, and pharmacokinetics (PK) of oral JNT-517 in adolescents (12 to less than 18 years of age) with PKU. Participants will receive either JNT-517 or placebo and will be blinded to their treatment assignment. Participants will have a 4 in 5 (or 80%) chance of receiving JNT-517. The study will last for up to 63 days including a Screening period, Treatment period and Follow-up period for safety. Participants will: * Take 75 mg JNT-517 or a placebo BID (2x per day) for 28 days * Visit the clinic or have a mobile health nurse visit your home for checkups and tests * Collect urine sample at home and bring to clinic on specified days * Keep a food diary 3 days before each study visit

Conditions

  • Phenylketonuria (PKU)

Interventions

  • JNT-517 TabletDrug

    JNT-517: 75 mg BID

  • PlaceboOther

    Placebo Tablet: BID

  • JNT-517 TabletDrug

    JNT-517: 150 mg BID

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of participants with treatment-emergent adverse events (TEAEs)Time frame: Screening to Study Completion (Average of 9 weeks)

Locations

7 sites in 2 countries. Site status is shown where the registry gives one.

  • University of Florida (UF) Health Shands Hospital

    Gainesville, Florida

  • University of South Florida

    Tampa, Florida

  • Oregon Health and Science University

    Portland, Oregon

  • Children's Medical Center Dallas

    Dallas, Texas

  • University of Texas Health (UTHealth) Science Center at Houston

    Houston, Texas

  • Utah Health - The University of Utah Hospital

    Salt Lake City, Utah

  • Murdoch Children's Research Institute

    Parkville, Melbourne, Victoria, Australia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.